The Journal of Urology
Volume 182, Issue 2 , Pages 616-625 , August 2009

Association of Lower Urinary Tract Symptoms and the Metabolic Syndrome: Results From the Boston Area Community Health Survey

  • Varant Kupelian

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • Corresponding Author InformationCorrespondence: New England Research Institutes, 9 Galen St., Watertown, Massachusetts 02472 (telephone: 617- 923-7747 ext 293; FAX: 617-924-0968)
    • ,
  • Kevin T. McVary

      Affiliations

    • Department of Urology, Northwestern University, Chicago, Illinois
    • Financial interest and/or other relationship with GlaxoSmithKline, Pfizer, Lilly/ICOS, Sanofi-Aventis, Allergan, and the National Institute of Diabetes and Digestive and Kidney Diseases.
    • ,
  • Steven A. Kaplan

      Affiliations

    • Cornell University, Weill Medical College, New York, New York
    • ,
  • Susan A. Hall

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • Carol L. Link

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • Lalitha Padmanabhan Aiyer

      Affiliations

    • Pfizer Inc, New York, New York
    • Financial interest and/or other relationship with Pfizer, Inc.
    • ,
  • Patrick Mollon

      Affiliations

    • Pfizer Ltd, Global Medical and Outcomes Research, Sandwich, United Kingdom
    • ,
  • Nihad Tamimi

      Affiliations

    • Pfizer Inc, New York, New York
    • Financial interest and/or other relationship with Pfizer, Inc.
    • ,
  • Raymond C. Rosen

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • Financial interest and/or other relationship with Pfizer Inc., Eli Lilly, Bayer Schering, Sanofi Aventis and Boehringer Ingelheim.
    • ,
  • John B. McKinlay

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • Requests for reprints: New England Research Institutes, 9 Galen St., Watertown, Massachusetts 02472 (telephone: 617-923-7747 ext. 512; FAX: 617-926-8246; e-mail: bach@neriscience.com).

Received 2 December 2008

  • Image Result

    Prevalence of MetS increases with increasing AUASI score in mild symptoms range (AUASI 2 to 7), and stabilizes with moderate (AUASI 8 to 19) and severe (AUASI 20 to 35) symptoms. Overall trend test p

    Prevalence of MetS increases with increasing AUASI score in mild symptoms range (AUASI 2 to 7), and stabilizes with moderate (AUASI 8 to 19) and severe (AUASI 20 to 35) symptoms. Overall trend test p = 0.003.

 Study received institutional review board approval.

 Supported by Pfizer, Inc.

 The BACH survey is supported by DK 56842 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.

PII: S0022-5347(09)00934-3

doi: 10.1016/j.juro.2009.04.025

The Journal of Urology
Volume 182, Issue 2 , Pages 616-625 , August 2009

Article Tools

* Image Usage & Resolution